Alligator Bioscience AB (ATORX) fair value: what the stock is really worth
We calculate from audited financials what Alligator Bioscience AB is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Sep 13, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Alligator Bioscience AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range kr 0.0192 – kr 204.42 · fair‑value band kr 0.0199 – kr 0.0222 · the kr 0.0193 price screens below the kr 0.0222 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Follow Alligator Bioscience in your weekly email
Every Wednesday you see whether Alligator Bioscience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium.
Show more
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 2 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, a monoclonal antibody that stimulates the 4-1BB receptor on T cells and NK cells in the tumor, which is in phase 1 for the treatment of solid metastatic cancers; and HLX22, an antibody that treats metastatic, gastric, and breast cancers, which is in phase 3 clinical trial. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; BioArctic AB; Henlius Biotech, Inc.; and Abclon Inc. The company was incorporated in 2000 and is headquartered in Lund, Sweden.
Stock analysis
Alligator Bioscience AB (ATORX) currently trades at kr 0.0193, while our model-based Fair Value estimate is kr 0.0222, implying the stock looks roughly 13.1% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.0199 (bear) to kr 0.0222 (bull), the price of kr 0.0193 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Alligator Bioscience AB reported revenue of 514K SEK in FY2025 versus 12.9M SEK in FY2021, a compound −55.4%/yr. Reported net income was −51.4M SEK in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 99% below its 52-week high and 1% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 15%, ATORX screens cheaper than that median.
Fair Value models
Bear kr 0.0199Fair Value kr 0.0222Bull kr 0.0222
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−99.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−75.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.8%
Start year 2020 (pandemic). Over 10 years: −46.9% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,315.7% (2020) → −21,738.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Alligator Bioscience AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 624 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Alligator Bioscience AB Fair Value". https://www.fairvalue-calculator.com/stock/ATORX
Frequently asked questions
Is Alligator Bioscience AB (ATORX) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of kr 0.0222 versus a price of kr 0.0193, about +15% upside (undervalued).
What is the fair value of ATORX?
Our model-based fair value for Alligator Bioscience AB is kr 0.0222 (as of Sep 13, 2026), built from audited fundamentals. The current price: kr 0.0193.
What is the quality score of ATORX?
Alligator Bioscience AB has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alligator Bioscience AB (ATORX)?
Our model-based price target is the fair value of kr 0.0222 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario kr 0.0199, optimistic scenario kr 0.0222. It is a calculation from audited fundamentals, not an analyst target.
What is the Alligator Bioscience AB stock forecast for 2026?
Our models put fair value at kr 0.0222, about +15% upside versus a price of kr 0.0193 (undervalued). Cautious scenario kr 0.0199, optimistic scenario kr 0.0222. The calculation is refreshed regularly with new filings.
What is the revenue of Alligator Bioscience AB (ATORX)?
Alligator Bioscience AB reported trailing-twelve-month revenue of about 520K SEK (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Alligator Bioscience AB (ATORX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alligator Bioscience AB it is kr 0.0222 per share (as of Sep 13, 2026), against a price of kr 0.0193. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Alligator Bioscience AB stock overvalued or undervalued in 2026?
As of Sep 13, 2026, ATORX trades below its calculated fair value: price kr 0.0193, fair value kr 0.0222, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATORX?
No. The price is what the market pays today (kr 0.0193); the fair value is what the company's own numbers justify (kr 0.0222). For Alligator Bioscience AB the two are kr 0.0029 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alligator Bioscience AB worth?
The market values Alligator Bioscience AB at about 117M SEK (market capitalisation, as of Sep 13, 2026). Per share that is kr 0.0193; our models calculate a fair value of kr 0.0222 per share.
What do the bullish and bearish scenarios say about ATORX?
Our models span a range for Alligator Bioscience AB: cautious scenario kr 0.0199, base kr 0.0222, optimistic kr 0.0222 per share (as of Sep 13, 2026, price kr 0.0193). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Alligator Bioscience AB (ATORX)?
Balance-sheet figures for Alligator Bioscience AB (as of Sep 13, 2026): debt of 1.08 per unit of equity. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is ATORX from its 52-week high?
Alligator Bioscience AB trades at kr 0.0193, about 99% below its 52-week high of kr 3.09 and 1% above the low of kr 0.0192 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0222 is for.
Which stocks are comparable to Alligator Bioscience AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alligator Bioscience AB stock attractive at the current price?
The data as of Sep 13, 2026: price kr 0.0193, calculated fair value kr 0.0222 (+15%), Quality Score 21/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ATORX calculated?
We run Alligator Bioscience AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.0222, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Alligator Bioscience AB currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alligator Bioscience AB (ATORX)?
The closing price on Oct 2, 2026 was kr 0.0193. Our model-based fair value is kr 0.0222, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alligator Bioscience AB right now?
The price is below even our cautious bear case (kr 0.0199). The market is more pessimistic than our downside scenario. The models converge in a tight band (kr 0.0199 to kr 0.0222), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Alligator Bioscience AB
How large is the market capitalisation of Alligator Bioscience AB (ATORX)?
The market capitalisation of Alligator Bioscience AB is 117M SEK (≈ $11.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Alligator Bioscience AB (ATORX)?
Earnings per share at Alligator Bioscience AB are kr −1.33. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Alligator Bioscience AB (ATORX)?
The return on equity (ROE) of Alligator Bioscience AB is −8,427% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alligator Bioscience AB (ATORX)?
On an EBIT basis the return on assets of Alligator Bioscience AB is −137% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alligator Bioscience AB (ATORX)?
The operating margin of Alligator Bioscience AB is −18,215% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alligator Bioscience AB (ATORX)?
Revenue at Alligator Bioscience AB is growing −69.3% versus a year earlier (3y avg −75.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Alligator Bioscience AB (ATORX) generate?
The free cash flow of Alligator Bioscience AB is −157M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Alligator Bioscience AB (ATORX) hold?
Alligator Bioscience AB holds more cash than debt, 19.0M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Alligator Bioscience AB in the live analysis
One click puts Alligator Bioscience AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
